NSB 0.00% 4.0¢ neuroscientific biopharmaceuticals ltd

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-3

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 1,587 Posts.
    lightbulb Created with Sketch. 310
    "New patent filed for the combination of EmtinB® and leading Multiple Sclerosis(MS) drug Copaxone®: MS is a complex neurological disease characterised by deterioration of the myelin sheath. An in-vitro study has reported that acombination of EmtinB® and Copaxone® has been shown to produce new myelin" - This is good news. - "Updated Atlas of MS Shows Over 2.8 Million People Worldwide Have Multiple Sclerosis -- with Nearly 1 Million in the US" (Sept 2020 )
 
watchlist Created with Sketch. Add NSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.